[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE60211317D1 - Rho-kinase inhibitoren - Google Patents

Rho-kinase inhibitoren

Info

Publication number
DE60211317D1
DE60211317D1 DE60211317T DE60211317T DE60211317D1 DE 60211317 D1 DE60211317 D1 DE 60211317D1 DE 60211317 T DE60211317 T DE 60211317T DE 60211317 T DE60211317 T DE 60211317T DE 60211317 D1 DE60211317 D1 DE 60211317D1
Authority
DE
Germany
Prior art keywords
rho
kinase inhibitors
kinase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60211317T
Other languages
English (en)
Other versions
DE60211317T2 (de
Inventor
Dhanapalan Nagarathnam
Davoud Asgari
Jianxing Shao
Xiao-Gao Liu
Uday Khire
Chunguang Wang
Barry Hart
Stephen Boyer
Olaf Weber
Mark Lynch
Donald Bankston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Application granted granted Critical
Publication of DE60211317D1 publication Critical patent/DE60211317D1/de
Publication of DE60211317T2 publication Critical patent/DE60211317T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60211317T 2001-03-23 2002-03-22 Rho-kinase inhibitoren Expired - Lifetime DE60211317T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27797401P 2001-03-23 2001-03-23
US277974P 2001-03-23
US31534101P 2001-08-29 2001-08-29
US315341P 2001-08-29
PCT/US2002/008659 WO2002076976A2 (en) 2001-03-23 2002-03-22 Rho-kinase inhibitors

Publications (2)

Publication Number Publication Date
DE60211317D1 true DE60211317D1 (de) 2006-06-14
DE60211317T2 DE60211317T2 (de) 2007-04-12

Family

ID=26958819

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60211317T Expired - Lifetime DE60211317T2 (de) 2001-03-23 2002-03-22 Rho-kinase inhibitoren

Country Status (20)

Country Link
US (3) US20030125344A1 (de)
EP (1) EP1370553B1 (de)
JP (1) JP4329003B2 (de)
AR (1) AR035791A1 (de)
AT (1) ATE325795T1 (de)
AU (1) AU2002250394A1 (de)
CA (1) CA2441492C (de)
CY (1) CY1107475T1 (de)
DE (1) DE60211317T2 (de)
DK (1) DK1370553T3 (de)
ES (1) ES2264477T3 (de)
HK (1) HK1061030A1 (de)
HN (1) HN2002000067A (de)
MX (1) MXPA03008658A (de)
MY (1) MY134783A (de)
PE (1) PE20021011A1 (de)
PT (1) PT1370553E (de)
TW (1) TWI261055B (de)
UY (1) UY27224A1 (de)
WO (1) WO2002076976A2 (de)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030087919A1 (en) * 2001-03-23 2003-05-08 Bayer Corporation Rho-kinase inhibitors
PT1370553E (pt) * 2001-03-23 2006-09-29 Bayer Corp Inibidores de rhoquinase
WO2002100833A1 (fr) * 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Inhibiteurs de rho kinase
JP4505228B2 (ja) * 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤
US7645878B2 (en) * 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US20050245509A1 (en) 2002-08-29 2005-11-03 Santen Pharmacecutical Co., Ltd. Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins
EP1608631A4 (de) 2003-03-28 2008-08-20 Scios Inc Bicyclische pyrimidininhibitoren von tgf beta
GB0307333D0 (en) * 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
EP1610774A4 (de) * 2003-04-09 2008-07-16 Exelixis Inc Tie-2 modulatoren und anwendungsverfahren
US20050014783A1 (en) * 2003-05-29 2005-01-20 Schering Aktiengesellschaft Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
US7410974B2 (en) * 2003-08-08 2008-08-12 Ulysses Pharmaceutical Products, Inc. Halogenated Quinazolinyl nitrofurans as antibacterial agents
US20080146562A1 (en) * 2003-08-08 2008-06-19 Ulysses Pharmaceutical Products Inc., Halogenated quinazolinyl nitrofurans as antibacterial agents
US20070123561A1 (en) * 2003-10-06 2007-05-31 Dennis Lee Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors
EP1670466A4 (de) * 2003-10-06 2007-04-25 Glaxo Group Ltd Zubereitung von 1,6,7-trisubstituierten azabenzimidazolen als kinasehemmer
JP4764823B2 (ja) * 2003-10-06 2011-09-07 グラクソ グループ リミテッド キナーゼ阻害剤としての１，６−二置換アザベンゾイミダゾールの調製
EP1679308B1 (de) 2003-10-15 2013-07-24 Ube Industries, Ltd. Neues indazolderivat
DE10357510A1 (de) * 2003-12-09 2005-07-07 Bayer Healthcare Ag Heteroarylsubstituierte Benzole
CN1933839A (zh) 2004-01-23 2007-03-21 安进公司 化合物和使用方法
WO2005073224A2 (en) 2004-01-23 2005-08-11 Amgen Inc Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
ES2315834T3 (es) 2004-02-03 2009-04-01 Astrazeneca Ab Derivados de quinazolina.
DE102004017438A1 (de) * 2004-04-08 2005-11-03 Bayer Healthcare Ag Hetaryloxy-substituierte Phenylaminopyrimidine
CN1988907B (zh) * 2004-06-01 2010-12-22 弗吉尼亚大学专利基金会 癌瘤及血管生成的双重小分子抑制剂
EP1781293A1 (de) 2004-06-04 2007-05-09 Amphora Discovery Corporation Verbindungen auf chinolin- und isochinolin-basis mit atp-verwendender enzymhemmender aktivität und zusammensetzungen und verwendungen daraus
JP2007269629A (ja) * 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
JP5046942B2 (ja) 2004-09-30 2012-10-10 テイボテク・フアーマシユーチカルズ Ｈｃｖ阻害性の二環式ピリミジン類
US7652009B2 (en) 2004-11-30 2010-01-26 Amgem Inc. Substituted heterocycles and methods of use
WO2007060028A1 (en) * 2004-12-31 2007-05-31 Gpc Biotech Ag Napthyridine compounds as rock inhibitors
JP2006219395A (ja) * 2005-02-09 2006-08-24 Koei Chem Co Ltd ビピリジン化合物の製造方法
NZ556248A (en) * 2005-03-14 2010-06-25 Neurosearch As Pyrazolyl-quinazoline potassium channel modulating agents and their medical use
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
WO2006100310A1 (en) 2005-03-25 2006-09-28 Tibotec Pharmaceuticals Ltd Heterobicylic inhibitors of hcv
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
RU2443688C2 (ru) 2005-06-28 2012-02-27 Санофи-Авентис ПРОИЗВОДНЫЕ ИЗОХИНОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
EP1932841B1 (de) 2005-08-30 2014-01-01 Asahi Kasei Pharma Corporation Sulfonamidverbindung
US8211919B2 (en) 2005-09-02 2012-07-03 Astellas Pharma Inc. Amide derivatives as rock inhibitors
JP5255559B2 (ja) * 2006-03-31 2013-08-07 アボット・ラボラトリーズ インダゾール化合物
EP2025676A4 (de) 2006-06-08 2011-06-15 Ube Industries Neues indazolderivat mit spiroringstruktur in der seitenkette
WO2007146230A2 (en) * 2006-06-14 2007-12-21 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
ME00811B (me) * 2006-12-08 2012-03-20 Novartis Ag JEDINJENJA l KOMPOZICIJE KAO INHIBITORI PROTEIN KINAZE
MY148427A (en) 2006-12-08 2013-04-30 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008079945A2 (en) * 2006-12-20 2008-07-03 University Of South Florida Rock inhibitors and uses thereof
MX2009007610A (es) 2007-02-06 2009-07-24 Boehringer Ingelheim Int Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion.
WO2008105058A1 (ja) 2007-02-27 2008-09-04 Asahi Kasei Pharma Corporation スルホンアミド化合物
WO2008105442A1 (ja) 2007-02-28 2008-09-04 Asahi Kasei Pharma Corporation スルホンアミド誘導体
AU2008272396B2 (en) 2007-07-02 2011-09-08 Asahi Kasei Pharma Corporation Sulfonamide Compound and Crystal Thereof
RU2474434C2 (ru) 2007-08-29 2013-02-10 Сэндзю Фармасьютикал Ко., Лтд. Средство для содействия адгезии роговичных эндотелиальных клеток
BRPI0907916A2 (pt) 2008-02-07 2015-07-28 Boehringer Ingelheim Int Heterociclos espirociclos, medicamentos contendo esses compostos, e processos para preparar os mesmos
BRPI0912170A2 (pt) 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
CN101463014B (zh) * 2008-12-26 2013-07-10 复旦大学 二芳基苯并嘧啶类衍生物及其药物组合物和用途
WO2010104851A1 (en) * 2009-03-09 2010-09-16 Surface Logix, Inc. Rho kinase inhibitors
EP3904505A1 (de) 2009-04-22 2021-11-03 Viacyte, Inc. Zellzusammensetzungen aus entdifferenzierten neuprogrammierten zellen
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
AU2010306627B2 (en) 2009-10-16 2014-07-17 The Scripps Research Institute Induction of pluripotent cells
EP2490701B9 (de) 2009-10-19 2017-11-15 Cellular Dynamics International, Inc. Herstellung von kardiomyozyten
WO2011062765A2 (en) * 2009-11-17 2011-05-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
US8759363B2 (en) 2010-01-28 2014-06-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Quinazoline-based T cell proliferation inhibitors
ES2552977T3 (es) * 2010-05-07 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Amino-quinolinas como inhibidores de quinasa
CN103003416B (zh) 2010-06-15 2016-11-16 细胞动力学国际有限公司 从小体积的外周血产生诱导性多潜能干细胞
BR112013008374A2 (pt) 2010-10-05 2016-06-14 Purdue Pharma Lp composto de quinazolina como bloqueador do canal de sódio
CN106893692B (zh) 2010-12-22 2021-11-26 菲特治疗公司 用于单细胞分选与增强ipsc重新编程的细胞培养平台
CN103857288B (zh) 2011-03-04 2016-09-21 葛兰素史密斯克莱知识产权发展有限公司 作为激酶抑制剂的氨基-喹啉
DK2694644T3 (en) 2011-03-30 2018-04-16 Cellular Dynamics Int Inc Priming of pluripotent stem cells for neural differentiation
JP6121658B2 (ja) * 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
WO2013009825A1 (en) 2011-07-11 2013-01-17 Cellular Dynamics International, Inc. Methods for cell reprogramming and genome engineering
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
PT2788472T (pt) 2011-12-06 2019-04-01 Astellas Inst For Regenerative Medicine Método de diferenciação dirigida para a produção de células endoteliais corneanas
ES2897740T3 (es) 2011-12-28 2022-03-02 Kyoto Prefectural Public Univ Corp Normalización del cultivo de células endoteliales de la córnea
EP2628482A1 (de) 2012-02-17 2013-08-21 Academisch Medisch Centrum Rho Kinase Inhibitoren in der Verwendung zur Behandlung von Neuroblastoma
EP2826855B1 (de) 2012-03-15 2018-08-29 iHeart Japan Corporation Myocardiale zellschicht
EP2837681B1 (de) 2012-04-06 2018-02-21 Kyoto University Verfahren zur induzierung erythropoietinproduzierender zellen
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
KR20150096794A (ko) 2012-12-21 2015-08-25 제니쓰 에피제네틱스 코포레이션 브로모도메인 저해제로서의 신규한 헤테로사이클릭 화합물
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
JP2016510000A (ja) 2013-02-20 2016-04-04 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物およびその使用
AU2014220300B2 (en) 2013-02-21 2016-10-13 Glaxosmithkline Intellectual Property Development Limited Quinazolines as kinase inhibitors
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US10266807B2 (en) 2013-04-03 2019-04-23 FUJIFILM Cellular Dynamics, Inc. Methods and compositions for culturing endoderm progenitor cells in suspension
US10961508B2 (en) 2013-04-12 2021-03-30 Kyoto University Method for inducing alveolar epithelial progenitor cells
CN105283542A (zh) 2013-06-11 2016-01-27 国立大学法人京都大学 产生肾前体细胞的方法及含有肾前体细胞的药物
JP6461118B2 (ja) * 2013-06-21 2019-01-30 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規の置換された二環式化合物
ES2806135T3 (es) 2013-06-21 2021-02-16 Zenith Epigenetics Ltd Nuevos inhibidores de bromodominios bicíclicos
EP3029140A4 (de) 2013-07-30 2017-06-28 Kyoto Prefectural Public University Corporation Hornhautendothel-zellmarker
US9855271B2 (en) 2013-07-31 2018-01-02 Zenith Epigenetics Ltd. Quinazolinones as bromodomain inhibitors
EP3031905A4 (de) 2013-08-07 2017-04-26 Kyoto University Verfahren zur herstellung bauchspeicheldrüsenhormon-produzierender zellen
ES2721440T3 (es) 2013-09-05 2019-07-31 Univ Kyoto Nuevo método para inducir células precursoras neurales productoras de dopamina
WO2015054317A1 (en) * 2013-10-07 2015-04-16 Kadmon Corporation, Llc Rho kinase inhibitors
PL3064222T3 (pl) 2013-10-31 2021-04-19 Kyoto Prefectural Public University Corporation Lek terapeutyczny zawierający inhibitor sygnału tgf-beta w chorobach związanych z retikulum endoplazmatycznym i śmiercią komórki w śródbłonku rogówki
JP6426194B2 (ja) 2013-11-01 2018-11-21 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態及びその使用
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
BR112016011096A2 (pt) 2013-11-27 2017-09-19 Kyoto Prefectural Public Univ Corp Aplicação de laminina à cultura de célula endotelial da córnea
WO2015112739A1 (en) * 2014-01-22 2015-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and method for treating parp1-deficient cancers
JP6722108B2 (ja) 2014-03-04 2020-07-15 フェイト セラピューティクス，インコーポレイテッド 改善された再プログラム方法及び細胞培養基盤
DK3119881T3 (da) 2014-03-21 2023-04-03 Fujifilm Cellular Dynamics Inc Production of midbrain dopaminergic neurons and methods for the use thereof
CN106536718B (zh) 2014-05-21 2021-04-27 国立大学法人京都大学 胰芽细胞的制造方法及含有胰芽细胞的胰疾病治疗剂
CN107075469A (zh) 2014-06-27 2017-08-18 加利福尼亚大学董事会 培养的哺乳动物角膜缘干细胞、其产生方法和其用途
CN105367555B (zh) * 2014-08-07 2019-06-25 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
EP3227280B1 (de) 2014-12-01 2019-04-24 Zenith Epigenetics Ltd. Substituierte pyridine als bromdomänenhemmer
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
WO2016092375A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
CN107406438B (zh) 2014-12-17 2021-05-14 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
US10711249B2 (en) 2014-12-26 2020-07-14 Kyoto University Method for inducing hepatocytes
US11021468B2 (en) 2015-04-01 2021-06-01 Rigel Pharmaceuticals, Inc. TGF-ß inhibitors
WO2017064119A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
EP4088719A1 (de) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur behandlung von kapillarer nichtperfusion der netzhaut
JP7263005B2 (ja) 2015-10-16 2023-04-24 フェイト セラピューティクス，インコーポレイテッド 基底状態の多能性の誘導及び維持に関するプラットフォーム
CA3003145A1 (en) 2015-10-30 2017-05-04 Gay M. Crooks Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
JP7008337B2 (ja) 2016-02-15 2022-02-10 京都府公立大学法人 ヒト機能性角膜内皮細胞およびその応用
WO2017183736A1 (ja) 2016-04-22 2017-10-26 国立大学法人京都大学 ドーパミン産生神経前駆細胞の製造方法
CN117467608A (zh) 2016-08-16 2024-01-30 富士胶片细胞动力股份有限公司 分化多能细胞的方法
EP3509423A4 (de) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. Kristalline formen von therapeutischen verbindungen und verwendungen davon
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN109688818A (zh) 2016-09-08 2019-04-26 卡拉制药公司 治疗化合物的晶型及其用途
CN106518790B (zh) * 2016-11-02 2019-01-15 河南省商业科学研究所有限责任公司 一种2,4-二氯喹唑啉的合成方法
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
US11718609B2 (en) 2016-12-13 2023-08-08 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
KR102594102B1 (ko) 2017-05-25 2023-10-25 고쿠리츠 다이가쿠 호진 교토 다이가쿠 중간 중배엽 세포로부터 신장 전구 세포로의 분화 유도 방법 및 다능성 줄기세포로부터 신장 전구 세포로의 분화 유도 방법
AU2018294054B2 (en) * 2017-06-30 2022-05-26 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
JP7039802B2 (ja) 2017-06-30 2022-03-23 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｒｈｏ－関連プロテインキナーゼ阻害剤、ｒｈｏ－関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用
EP3421465B1 (de) 2017-06-30 2022-10-26 Beijing Tide Pharmaceutical Co., Ltd. Rho-assoziierte proteinkinasehemmer, pharmazeutische zusammensetzung damit sowie herstellungsverfahren und verwendung davon
CN111587112B (zh) * 2017-09-01 2023-10-10 卡德门企业有限公司 Rho相关含卷曲螺旋蛋白激酶的抑制剂
US20210363483A1 (en) 2017-11-10 2021-11-25 Regenesis Science Co., Ltd. Method for producing cultured cell, and method for producing therapeutic agent for spinal cord injury disease
AU2018369784B2 (en) 2017-11-14 2023-06-01 Massachusetts Eye And Ear Infirmary RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
TWI833535B (zh) 2017-12-21 2024-02-21 日商參天製藥股份有限公司 賽佩普斯特(Sepetaprost)及Rho激酶抑制劑之組合醫藥
WO2019131940A1 (ja) 2017-12-28 2019-07-04 株式会社カネカ 多能性幹細胞凝集抑制剤
WO2019131942A1 (ja) 2017-12-28 2019-07-04 株式会社カネカ 細胞凝集促進剤
CN111788300B (zh) 2017-12-28 2024-08-13 株式会社钟化 细胞聚集抑制剂
US20200405768A1 (en) 2018-02-19 2020-12-31 Sumitomo Dainippon Pharma Co., Ltd. Cell Aggregate, Mixture of Cell Aggregates, and Method for Preparing Same
EP3828262A4 (de) 2018-07-23 2022-03-30 Kyoto University Neuer marker für nierenvorläuferzellen und verfahren zur konzentration von nierenvorläuferzellen unter verwendung desselben
WO2020047229A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
WO2020045642A1 (ja) 2018-08-31 2020-03-05 学校法人同志社 眼細胞を保存または培養するための組成物および方法
CN113015429A (zh) 2018-10-02 2021-06-22 学校法人同志社 用于保存角膜内皮细胞的方法和容器
UY38427A (es) 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
WO2020130147A1 (ja) 2018-12-21 2020-06-25 国立大学法人京都大学 ルブリシン局在軟骨様組織、その製造方法及びそれを含む関節軟骨損傷治療用組成物
WO2020193802A1 (en) 2019-03-28 2020-10-01 Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe Polymeric conjugates and uses thereof
WO2020203538A1 (ja) 2019-03-29 2020-10-08 株式会社カネカ 多能性幹細胞を含む細胞集団及びその製造方法
KR20220008894A (ko) 2019-05-15 2022-01-21 아지노모토 가부시키가이샤 신경제세포 또는 각막 상피 세포의 순화 방법
CN115427551A (zh) 2020-02-27 2022-12-02 京都府公立大学法人 人功能性角膜内皮细胞及其应用
US20230348852A1 (en) 2020-04-27 2023-11-02 Novartis Ag Methods and compositions for ocular cell therapy
US20240010989A1 (en) 2021-01-08 2024-01-11 Kyoto University Medium for culturing and expanding nephron progenitor cells, method for culturing and expanding nephron progenitor cells, and method for producing renal organoids
CA3207859A1 (en) 2021-01-11 2022-07-14 Incyte Corporation Combination therapy comprising jak pathway inhibitor and rock inhibitor
US20240219375A1 (en) 2021-04-07 2024-07-04 FUJIFILM Cellular Dynamics, Inc. Dopaminergic precursor cells and methods of use
WO2022235586A1 (en) 2021-05-03 2022-11-10 Astellas Institute For Regenerative Medicine Methods of generating mature corneal endothelial cells
JPWO2022259721A1 (de) 2021-06-10 2022-12-15
JPWO2023017848A1 (de) 2021-08-11 2023-02-16
JP2024531682A (ja) 2021-09-13 2024-08-29 フジフィルム セルラー ダイナミクス，インコーポレイテッド コミットされた心臓始原細胞の製造方法
KR20240110954A (ko) 2021-11-11 2024-07-16 학교법인 도시샤 각막 내피 세포의 냉동보존 제제 및 상기 냉동보존 제제를 생산하기 위한 방법
KR20240103018A (ko) 2021-11-19 2024-07-03 고쿠리쓰 겐큐 가이하쓰 호징 리가가쿠 겐큐소 시트상 망막 조직의 제조 방법
CN118679244A (zh) 2022-02-09 2024-09-20 住友制药株式会社 判定培养液中的细胞在由多能干细胞向中脑底板区域的神经系统细胞的分化中的分化能力的方法
WO2024073776A1 (en) 2022-09-30 2024-04-04 FUJIFILM Cellular Dynamics, Inc. Methods for the production of cardiac fibroblasts

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US14679A (en) * 1856-04-15 Joel h
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
US4642347A (en) * 1985-05-21 1987-02-10 American Home Products Corporation 3(2-quinolinylalkoxy)phenols
US5245038A (en) * 1987-11-06 1993-09-14 Baxter Diagnostics Inc. Fluorescent poly(arylpyridine) rare earth chelates
IL89029A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US4952567A (en) * 1988-05-09 1990-08-28 City Of Hope Inhibition of lipogenesis
US6004979A (en) * 1991-02-07 1999-12-21 Hoechst Marion Roussel Nitrogenous bicycles
JP3531944B2 (ja) * 1991-02-07 2004-05-31 アベンティス・ファーマ・ソシエテ・アノニム 新規のベンジル基で置換された窒素系二環式誘導体及びその製造方法
MX9200299A (es) * 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US6645969B1 (en) * 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5245036A (en) * 1992-05-07 1993-09-14 Dowelanco Process for the preparation of 4-phenoxyquinoline compounds
US5972598A (en) * 1992-09-17 1999-10-26 Board Of Trustess Of The University Of Illinois Methods for preventing multidrug resistance in cancer cells
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
EP1195372A1 (de) * 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-Heterozyklisch substitutierte Benzamid Deriviate mit antihypertensiver Wirkung
US5840695A (en) * 1994-10-07 1998-11-24 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US5906819A (en) * 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
DE19608653A1 (de) * 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
PT912559E (pt) * 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
BR9711154A (pt) * 1996-08-12 1999-08-17 Yoshitomi Pharmaceutical Agente farmac-utico contendo inibidor cinase rho
AR012634A1 (es) * 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US5885803A (en) * 1997-06-19 1999-03-23 Incyte Pharmaceuticals, Inc. Disease associated protein kinases
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
CA2342503A1 (en) * 1998-08-21 2000-03-02 Parker Hughes Institute Quinazoline derivatives
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
DE59913467D1 (en) * 1998-12-23 2006-06-29 Bayer Materialscience Ag Polycarbonate mit niedrigem yellowness-index
GB2345486A (en) * 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
ATE482946T1 (de) * 1999-02-10 2010-10-15 Astrazeneca Ab Chinazolinderivate als angiogenesehemmer und zwischenprodukte dafür
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AU2002234047A1 (en) * 2000-12-21 2002-07-01 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
PT1370553E (pt) * 2001-03-23 2006-09-29 Bayer Corp Inibidores de rhoquinase
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
NZ532524A (en) * 2001-11-03 2007-02-23 Astrazeneca Ab Quinazoline derivatives as antitumor agents
GB0128108D0 (en) * 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
JP4505228B2 (ja) * 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤
WO2003062227A1 (en) * 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
NZ534171A (en) * 2002-02-01 2007-06-29 Astrazeneca Ab Quinazoline compounds for the treatment of diseases associated with angiogenesis and/or increased vascular permeability
WO2004081009A1 (en) * 2003-03-12 2004-09-23 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as tgf-beta inhibitors
GB0318422D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
ES2354457T3 (es) * 2005-09-20 2011-03-15 Astrazeneca Ab Compuestos de 4-(1h-indazol-5-il-amino)-quinazolina como inhibidores del receptor erbb de la tirosina quinasa para el tratamiento del cáncer.

Also Published As

Publication number Publication date
MY134783A (en) 2007-12-31
WO2002076976A3 (en) 2002-12-12
ATE325795T1 (de) 2006-06-15
JP2004524350A (ja) 2004-08-12
CA2441492C (en) 2011-08-09
HN2002000067A (es) 2003-10-24
EP1370553B1 (de) 2006-05-10
PT1370553E (pt) 2006-09-29
JP4329003B2 (ja) 2009-09-09
HK1061030A1 (en) 2004-09-03
US20060142313A1 (en) 2006-06-29
US20030125344A1 (en) 2003-07-03
US20100137324A1 (en) 2010-06-03
TWI261055B (en) 2006-09-01
DE60211317T2 (de) 2007-04-12
DK1370553T3 (da) 2006-09-11
CA2441492A1 (en) 2002-10-03
MXPA03008658A (es) 2005-04-11
WO2002076976A2 (en) 2002-10-03
AU2002250394A1 (en) 2002-10-08
UY27224A1 (es) 2002-10-31
CY1107475T1 (el) 2013-03-13
ES2264477T3 (es) 2007-01-01
EP1370553A2 (de) 2003-12-17
AR035791A1 (es) 2004-07-14
PE20021011A1 (es) 2003-02-01

Similar Documents

Publication Publication Date Title
DE60211317D1 (de) Rho-kinase inhibitoren
DE60218138D1 (de) Rho-kinase inhibitoren
DE60320933D1 (de) Rho-kinase inhibitoren
DE60234125D1 (de) E inhibitoren
NO20041293D0 (no) Alkyn-aryl-fosfodiesterase-4-inhibitorer
CY2015028I2 (el) Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης
ATE484496T1 (de) Metalloproteinaseinhibitoren
EE200300439A (et) Metalloproteinaasi inhibiitorid
ATE286049T1 (de) Pyridazinonaldose reductase inhibitoren
ATE524441T1 (de) Vla-4-inhibitoren
NO20034308L (no) Nye tyrokinase-inhibitorer
ATE505471T1 (de) Azaindol-kinaseinhibitoren
DE60230934D1 (de) Fab-i-inhibitoren
EE200300452A (et) Metalloproteinaasi inhibiitorid
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
NO20032807D0 (no) Substituerte 8-arylkinolin-fosfodiesterase-4-inhibitorer
PT1339695E (pt) Inibidores da farnesiltransferase
AR028075A1 (es) Inhibidores de la peptido-desformilasa
DE60132468D1 (de) Alen-lanosterol zyklase inhibitoren
DOP2001000307A (es) Inhibidores de thrombin
SE0100694D0 (sv) DHFR inhibitors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BAYER PHARMACEUTICALS CORP., WEST HAVEN, CONN., US

8327 Change in the person/name/address of the patent owner

Owner name: BAYER HEALTHCARE, LLC, TARRYTOWN, N.Y., US